COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin

Cisplatin-based therapy is highly toxic, but moderately effective in most cancers. Concurrent inhibition of cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH) results in antitumor activity and has organ-protective effects. The goal of this study was to determine the antitumor activity of PTUPB, an orally bioavailable COX-2/sEH dual inhibitor, in combination with cisplatin and gemcitabine (GC) therapy. NSG mice bearing bladder cancer patient-derived xenografts were treated with vehicle, PTUPB, cisplatin, GC, or combinations thereof. Mouse experiments were performed with two different PDX models. PTUPB potentiated cisplatin and GC therapy, resulting in significantly reduced tumor growth and prolonged survival. PTUPB plus cisplatin was no more toxic than cisplatin single-agent treatment as assessed by body weight, histochemical staining of major organs, blood counts, and chemistry. The combination of PTUPB and cisplatin increased apoptosis and decreased phosphorylation in the MAPK/ERK and PI3K/AKT/mTOR pathways compared with controls. PTUPB treatment did not alter platinum–DNA adduct levels, which is the most critical step in platinum-induced cell death. The in vitro study using the combination index method showed modest synergy between PTUPB and platinum agents only in 5637 cell line among several cell lines examined. However, PTUPB is very active in vivo by inhibiting angiogenesis. In conclusion, PTUPB potentiated the antitumor activity of cisplatin-based treatment without increasing toxicity in vivo and has potential for further development as a combination chemotherapy partner. Mol Cancer Ther; 17(2); 474–83. ©2017 AACR.

[1]  Susan Airhart,et al.  Microdose-Induced Drug–DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice , 2016, Molecular Cancer Therapeutics.

[2]  J. Coward,et al.  Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. , 2016, Critical reviews in oncology/hematology.

[3]  S. Goswami,et al.  Anti-Ulcer Efficacy of Soluble Epoxide Hydrolase Inhibitor TPPU on Diclofenac-Induced Intestinal Ulcers , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[4]  Joseph Cheriyan,et al.  Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor. , 2016, British journal of clinical pharmacology.

[5]  K. Turteltaub,et al.  Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer , 2016, PloS one.

[6]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[7]  C. Bult,et al.  Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy , 2015, PloS one.

[8]  Philip Levy Ho,et al.  Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance , 2014, Nature.

[9]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[10]  S. Hwang,et al.  Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis , 2014, Proceedings of the National Academy of Sciences.

[11]  Nimit L. Patel,et al.  COX-2 Inhibition Potentiates Antiangiogenic Cancer Therapy and Prevents Metastasis in Preclinical Models , 2014, Science Translational Medicine.

[12]  Dafydd G. Thomas,et al.  Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer , 2013, Molecular medicine.

[13]  D. Holt,et al.  Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase. , 2013, Bioorganic & medicinal chemistry letters.

[14]  B. Hammock,et al.  Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. , 2013, Annual review of pharmacology and toxicology.

[15]  B. Hammock,et al.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. , 2012, Journal of medicinal chemistry.

[16]  Sampathkumar Anandan,et al.  Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single‐ and Multiple‐Dose Studies in Healthy Human Subjects , 2012, Journal of clinical pharmacology.

[17]  O. Dalesio,et al.  Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Hammock,et al.  Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception. , 2011, Prostaglandins & other lipid mediators.

[19]  Laurel Beckett,et al.  A microdosing approach for characterizing formation and repair of carboplatin–DNA monoadducts and chemoresistance , 2011, International journal of cancer.

[20]  S. Hwang,et al.  Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. , 2011, Journal of medicinal chemistry.

[21]  J L Sebaugh,et al.  Guidelines for accurate EC50/IC50 estimation , 2011, Pharmaceutical statistics.

[22]  P. Henderson,et al.  Human microdosing for the prediction of patient response. , 2010, Bioanalysis.

[23]  S. Hwang,et al.  Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. , 2010, Biochemical pharmacology.

[24]  S. Mandal,et al.  COX-2 as a target for cancer chemotherapy , 2010, Pharmacological reports : PR.

[25]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[26]  Paul D. Jones,et al.  Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways , 2008, Proceedings of the National Academy of Sciences.

[27]  S. Hwang,et al.  Orally bioavailable potent soluble epoxide hydrolase inhibitors. , 2007, Journal of medicinal chemistry.

[28]  A. Rossi,et al.  Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. , 2007, The Lancet. Oncology.

[29]  A. A. Spector,et al.  Action of epoxyeicosatrienoic acids on cellular function. , 2007, American journal of physiology. Cell physiology.

[30]  B. Hammock,et al.  Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors , 2006, Proceedings of the National Academy of Sciences.

[31]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[32]  Liang Cheng,et al.  A Phase II Trial of Irinotecan, 5-Fluorouracil and Leucovorin Combined with Celecoxib and Glutamine as First-Line Therapy for Advanced Colorectal Cancer , 2005, Oncology.

[33]  B. Hammock,et al.  Soluble epoxide hydrolase is a therapeutic target for acute inflammation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Graham Bench,et al.  A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry. , 2003, Analytical chemistry.

[35]  Xiang Fang,et al.  Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. , 2004, Progress in lipid research.

[36]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.